Ronopterin is under clinical development by VeriNOS operations and currently in Phase I for Traumatic Brain Injury. According to GlobalData, Phase I drugs for Traumatic Brain Injury does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ronopterin LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ronopterin overview

Ronopterin (VAS-203) is under development for the treatment of moderate to severe traumatic brain injury (TBI), glioblastoma multiforme (GBM), diabetic retinopathy and metastatic brain tumor. The drug candidate is administered through intravenous infusion. The drug candidate acts by targeting nitric oxide (NO) synthase.

VeriNOS operations overview

veriNOS operations (vasopharm), formerly vasopharm GmbH, is a drug company that develops novel therapeutics for the treatment of Cerebro and cardiovascular diseases. The company provides products such as VAS203, an allosteric NO synthase inhibitor that is used for traumatic brain injury and parenchyma. Its VAS2870 is used for the treatment of peripheral arterial occlusive diseases. vasopharm provides drug development in acute niche indications by targeting pathological nitric oxide production and signaling from discovery to a pivotal clinical trial. It also offers treatment in the areas of acute cardiovascular and central nervous system diseases. vasopharm is headquartered in Wurzburg, Germany.

For a complete picture of Ronopterin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.